(Q38458762)

3 September 2017

title

Status of HER-2 in male and female breast carcinoma (English)

1 reference

3 September 2017

Bloom KJ

1

1 reference

3 September 2017

Govil H

2

1 reference

3 September 2017

Gattuso P

3

1 reference

3 September 2017

Reddy V

4

1 reference

3 September 2017

Francescatti D

5

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

The American Journal of Surgery

3 September 2017

published in

1 reference

3 September 2017

volume

182

1 reference

3 September 2017

issue

4

1 reference

3 September 2017

page(s)

389-392

1 reference

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

C-erbB-2 immunostaining: problems with interpretation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

The significance of oncogene amplification in primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2801%2900733-4

10.1016/S0002-9610(01)00733-4

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference